Subject(s)
Bacterial Load , Enterobacteriaceae Infections/diagnosis , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/physiopathology , Enterobacteriaceae/isolation & purification , Enterobacteriaceae/metabolism , Feces/microbiology , beta-Lactamases/metabolism , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Inpatients/statistics & numerical data , Male , Middle Aged , Prospective Studies , Young AdultABSTRACT
Enterobacter species are Gram-negative, non-spore-forming, facultative anaerobes typically motile due to the presence of peritrichous flagella. E. cloacae, the species responsible for the majority of Enterobacter infections in humans, is part of the intestinal microbiota and may cause infection in patients that have previously received antimicrobial therapy or who have been admitted to the Intensive Care Unit. E. cloacae may cause several infections, such as pneumonia, urinary tract, skin and soft tissue and intravascular infections. Infective Endocarditis (IE) is a rare disease with notable morbidity and mortality. Even though IE is rarely caused by E. cloacae, these infections can be problematic due to the relative lack of experience in their management. The purpose of this study was to systematically review all published cases of IE by E. cloacae in the literature. A systematic review of PubMed, Scopus and Cochrane library (through 14th November 2020) for studies providing epidemiological, clinical, microbiological as well as treatment data and outcomes of IE by E. cloacae was performed. A total of 20 studies, containing data of 20 patients, were included. A prosthetic valve was present in 27.8%. Mitral valve was the commonest infected site, followed by aortic valve. Diagnosis was facilitated by transthoracic and transesophageal echocardiography in 38.5% each, while the diagnosis was set at autopsy in 10%. Fever, sepsis, shock and immunologic phenomena were the most common clinical presentations, followed by heart failure. Aminoglycosides, cephalosporins and carbapenems were the most common antimicrobials used. Clinical cure was noted in 75%, while overall mortality was 30%. Development of shock and treatment with the combination of piperacillin with tazobactam were associated with overall mortality.
Subject(s)
Endocarditis, Bacterial/physiopathology , Enterobacter cloacae , Enterobacteriaceae Infections/physiopathology , Anti-Bacterial Agents/therapeutic use , Aortic Valve , Echocardiography , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/epidemiology , Endocarditis, Bacterial/microbiology , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Heart Valve Prosthesis/microbiology , Humans , Mitral ValveABSTRACT
Edwardsiella piscicida is an intracellular pathogen within a broad spectrum of hosts. Essential to E. piscicida's virulence is its ability to invade and replicate inside host cells, yet the survival mechanisms and the nature of the replicative compartment remain unknown. Here, we characterized its intracellular lifestyle in nonphagocytic cells and showed that the intracellular replication of E. piscicida in nonphagocytic cells is dependent on its type III secretion system (T3SS) but not its type VI secretion system. Following internalization, E. piscicida is contained in vacuoles that transiently mature into early endosomes but subsequently bypasses the classical endosome pathway and fusion with lysosomes, which depend on its T3SS. Following rapid escape from the degradative pathway, E. piscicida was found to create a specialized replication-permissive niche characterized by endoplasmic reticulum (ER) markers. Furthermore, we found that a T3SS effector, EseJ, is responsible for the intracellular replication of E. piscicida by preventing endosome/lysosome fusion. In vivo experiments also confirmed that EseJ is necessary for bacterial colonization by E. piscicida in the epithelial layer, followed by systemic dissemination in both zebrafish and mice. Thus, this work elucidates the tactics used by E. piscicida to survive and proliferate within host nonphagocytic cells. IMPORTANCEE. piscicida is a facultative intracellular bacterium associated with septicemia and fatal infections in many animals, including fish and humans. However, little is known about its intracellular life, which is important for successful invasion of the host. The present study is the first comprehensive characterization of E. piscicida's intracellular lifestyle in host cells. Upon internalization, E. piscicida is transiently contained in Rab5-positive vacuoles, but the pathogen prevents further endosome maturation and fusion with lysosomes by utilizing a T3SS effector, EseJ. In addition, the bacterium creates a specialized replication niche for rapid growth via an interaction with the ER. Our study provides new insights into the strategies used by E. piscicida to successfully establish an intracellular lifestyle that contributes to its survival and dissemination during infection.
Subject(s)
Edwardsiella/physiology , Endocytosis , Enterobacteriaceae Infections/microbiology , Host-Pathogen Interactions , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , DNA Replication , Edwardsiella/genetics , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum/microbiology , Enterobacteriaceae Infections/physiopathology , Humans , Mice , Mice, Inbred C57BL , Type III Secretion Systems/genetics , Type III Secretion Systems/metabolism , Type VI Secretion Systems/genetics , Type VI Secretion Systems/metabolism , Vacuoles/metabolism , Vacuoles/microbiology , ZebrafishABSTRACT
A 63-year-old diabetic smoker with alcoholism was the first mortality case of coronavirus disease 2019 (COVID-19) in Taiwan. As concurrently infected with Klebsiella pneumoniae and subsequently with Klebsiella aerogenes, he was exposed by a national survey of patients with critically influenza-negative pneumonia. We recommend COVID-19 screening for patients with severe flu-like syndrome and protecting health-care workers from being infected.
Subject(s)
Coinfection , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Enterobacteriaceae Infections/diagnosis , Enterobacteriaceae Infections/therapy , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Betacoronavirus , COVID-19 , Coinfection/microbiology , Coinfection/virology , Coronavirus Infections/pathology , Coronavirus Infections/physiopathology , Critical Care , Critical Illness , Enterobacteriaceae Infections/pathology , Enterobacteriaceae Infections/physiopathology , Fatal Outcome , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/pathology , Pneumonia, Viral/physiopathology , SARS-CoV-2 , TaiwanABSTRACT
Infection with carbapenem-resistant Enterobacteriaceae (CRE) has become an important challenge in health care settings and a growing concern worldwide. Since infection is preceded by colonization, an understanding of the latter may reduce CRE infections. We aimed to characterize the gut microbiota in CRE carriers, assuming that microbiota alterations precede CRE colonization. We evaluated the gut microbiota using 16S rRNA gene sequencing extracted of fecal samples collected from hospitalized CRE carriers and two control groups, hospitalized noncarriers and healthy adults. The microbiota diversity and composition in CRE-colonized patients differed from those of the control group participants. These CRE carriers displayed lower phylogenetic diversity and dysbiotic microbiota, enriched with members of the family Enterobacteriaceae Concurrent with the enrichment in Enterobacteriaceae, a depletion of anaerobic commensals was observed. Additionally, changes in several predicted metabolic pathways were observed for the CRE carriers. Concomitantly, we found higher prevalence of bacteremia in the CRE carriers. Several clinical factors that might induce changes in the microbiota were examined and found to be insignificant between the groups. The compositional and functional changes in the microbiota of CRE-colonized patients are associated with increased risk for systemic infection. Our study results provide justification for attempts to restore the dysbiotic microbiota with probiotics or fecal transplantation.IMPORTANCE The gut microbiota plays important roles in the host's normal function and health, including protection against colonization by pathogenic bacteria. Alterations in the gut microbial profile can potentially serve as an early diagnostic tool, as well as a therapeutic strategy against colonization by and carriage of harmful bacteria, including antibiotic-resistant pathogens. Here, we show that the microbiota of hospitalized patients demonstrated specific taxa which differed between carriers of carbapenem-resistant Enterobacteriaceae (CRE) and noncarriers. The difference in the microbiota also dictates alterations in microbiome-specific metabolic capabilities, in association with increased prevalence of systemic infection. Reintroducing specific strains and/or correction of dysbiosis with probiotics or fecal transplantation may potentially lead to colonization by bacterial taxa responsible for protection against or depletion of antibiotic-resistant pathogens.
Subject(s)
Carbapenem-Resistant Enterobacteriaceae/pathogenicity , Carrier State/microbiology , Dysbiosis/microbiology , Enterobacteriaceae Infections/physiopathology , Intestines/physiopathology , Adolescent , Adult , Aged , Aged, 80 and over , Carbapenem-Resistant Enterobacteriaceae/drug effects , Carbapenem-Resistant Enterobacteriaceae/genetics , Carbapenems/pharmacology , Cohort Studies , Enterobacteriaceae Infections/microbiology , Feces/microbiology , Female , Gastrointestinal Microbiome , Humans , Intestines/microbiology , Male , Metabolic Networks and Pathways , Middle Aged , Phylogeny , RNA, Ribosomal, 16S/genetics , Young AdultABSTRACT
This study aimed to assess the clinical impact and potential risk factors associated with polymyxin-resistant Enterobacteriaceae strains isolated from patients hospitalized in adult and neonatal intensive care units. A case-control study was conducted from September 2015 to January 2017. Antimicrobial susceptibility of polymyxin-resistant Enterobacteriaceae strains was determined by broth microdilution. The presence of resistance genes was evaluated by polymerase chain reaction and DNA sequencing. Renal failure [P=0.02, odds ratio (OR) 11.37, 95% confidence interval (CI) 1.0-128.63], use of a urinary catheter (P<0.01, OR 4.16, 95% CI 38.82-366.07), transfer between hospital units (P=0.03, OR 9.98, 95% CI 1.01-98.42), carbapenem use (P<0.01, OR 45.49, 95% CI 6.93-298.62) and surgical procedure (P<0.01, OR 16.52, 95% CI 2.83-96.32) were found to be risk factors for the acquisition of polymyxin-resistant strains in adult patients. For neonatal patients, use of a central venous catheter (P<0.01, OR 69.59, 95% CI 7.33-660.30) was the only risk factor associated with the acquisition of polymyxin-resistant strains. Analysis of the outcomes revealed that the mortality rate was significantly higher in adult (66.6%) and neonatal (23.5%) patients with polymyxin-resistant strains than in those with polymyxin-susceptible strains. In addition, carbapenem exposure (P<0.01, OR 50.93, 95% CI 2.26->999.999) was strongly associated with mortality. On the other hand, aminoglycoside use (P<0.03, OR 0.06, 95% CI 0.004-0.97) was a protective factor against mortality from polymyxin-resistant strains. Several risk factors were associated with polymyxin-resistant strains. The high mortality rates showed that acquisition of these strains is a predictor for unfavourable outcomes. Combination treatment with an aminoglycoside and polymyxin might be a better combination to improve patient outcomes.
Subject(s)
Anti-Bacterial Agents/pharmacology , Carbapenem-Resistant Enterobacteriaceae , Enterobacteriaceae Infections , Polymyxins/pharmacology , Aminoglycosides/pharmacology , Aminoglycosides/therapeutic use , Anti-Bacterial Agents/therapeutic use , Carbapenems/pharmacology , Carbapenems/therapeutic use , Critical Illness/epidemiology , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/physiopathology , Humans , Risk FactorsABSTRACT
BACKGROUND: Urinary tract infections (UTI) are among the most frequent bacterial infections in older adults. The aim of the study was to analyse the existence of differences in clinical features, microbiological data and risk of infection by multidrug-resistant organisms (MDRO) between older and non-older men with febrile UTI (FUTI). METHODS: This was an ambispective observational study involving older males with a FUTI attended in the Emergency Department. Variables collected included age, comorbidity, diagnostic of healthcare-associated (HCA)-FUTI, clinical manifestations, hospitalization, mortality, and microbiological data. RESULTS: Five hundred fifty-two males with a FUTI, 329 (59.6%) of whom were older adults, were included. Older males had a higher frequency of HCA-FUTI (p < 0.001), increased Charlson scores (p < 0.001), had received previous antimicrobial treatment more frequently (p < 0.001) and had less lower urinary tract symptoms (p < 0.001). Older patients showed a lower frequency of FUTI caused by E. coli (p < 0.001) and a higher rate of those due to Enterobacter spp. (p = 0.003) and P. aeruginosa (p = 0.033). Resistance rates to cefuroxime (p = 0.038), gentamicin (p = 0.043), and fluoroquinolones (p < 0.001) in E. coli isolates and the prevalence of extended-spectrum beta-lactamase and AmpC producing E. coli and Klebsiella spp. strains (p = 0.041) and MDRO (p < 0.001) were increased in older males. Inadequate empirical antimicrobial treatment (p = 0.004), frequency of hospitalization (p < 0.001), and all cause in-hospital mortality (p = 0.007) were higher among older patients. In the multivariate analysis, being admitted from an long term care facility (OR 2.4; 95% CI: 1.06-5.9), having a urinary tract abnormality (OR 2.2; 95% CI: 1.2-3.8) and previous antimicrobial treatment (OR 3.2; 95% CI: 1.9-5.4) were associated to FUTI caused by MDRO. CONCLUSIONS: Older male adults with a FUTI have different clinical characteristics, present specific microbiological features, and antimicrobial resistance rates. In the multivariate analysis being an older male was not associated with an increased risk of FUTI caused by MDRO.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Enterobacteriaceae Infections/diagnosis , Escherichia coli Infections/diagnosis , Fever/diagnosis , Urinary Tract Infections/diagnosis , Adult , Aged , Aged, 80 and over , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/physiopathology , Escherichia coli Infections/drug therapy , Escherichia coli Infections/physiopathology , Fever/drug therapy , Fever/physiopathology , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Urinary Tract Infections/drug therapy , Urinary Tract Infections/physiopathologyABSTRACT
Parkinson's disease is a neurodegenerative disorder with motor symptoms linked to the loss of dopaminergic neurons in the substantia nigra compacta. Although the mechanisms that trigger the loss of dopaminergic neurons are unclear, mitochondrial dysfunction and inflammation are thought to have key roles1,2. An early-onset form of Parkinson's disease is associated with mutations in the PINK1 kinase and PRKN ubiquitin ligase genes3. PINK1 and Parkin (encoded by PRKN) are involved in the clearance of damaged mitochondria in cultured cells4, but recent evidence obtained using knockout and knockin mouse models have led to contradictory results regarding the contributions of PINK1 and Parkin to mitophagy in vivo5-8. It has previously been shown that PINK1 and Parkin have a key role in adaptive immunity by repressing presentation of mitochondrial antigens9, which suggests that autoimmune mechanisms participate in the aetiology of Parkinson's disease. Here we show that intestinal infection with Gram-negative bacteria in Pink1-/- mice engages mitochondrial antigen presentation and autoimmune mechanisms that elicit the establishment of cytotoxic mitochondria-specific CD8+ T cells in the periphery and in the brain. Notably, these mice show a sharp decrease in the density of dopaminergic axonal varicosities in the striatum and are affected by motor impairment that is reversed after treatment with L-DOPA. These data support the idea that PINK1 is a repressor of the immune system, and provide a pathophysiological model in which intestinal infection acts as a triggering event in Parkinson's disease, which highlights the relevance of the gut-brain axis in the disease10.
Subject(s)
Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/physiopathology , Intestines/microbiology , Parkinson Disease/genetics , Parkinson Disease/microbiology , Protein Kinases/deficiency , Protein Kinases/genetics , Animals , Antigen Presentation/immunology , Autoantigens/immunology , Axons/pathology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/pathology , Citrobacter rodentium/immunology , Citrobacter rodentium/pathogenicity , Disease Models, Animal , Dopaminergic Neurons/immunology , Dopaminergic Neurons/pathology , Enterobacteriaceae Infections/immunology , Enterobacteriaceae Infections/pathology , Female , Intestines/immunology , Intestines/pathology , Levodopa/therapeutic use , Male , Mice , Mitochondria/immunology , Mitochondria/pathology , Neostriatum/immunology , Neostriatum/microbiology , Neostriatum/pathology , Neostriatum/physiopathology , Parkinson Disease/drug therapy , Parkinson Disease/physiopathology , Protein Kinases/immunology , Ubiquitin-Protein Ligases/deficiency , Ubiquitin-Protein Ligases/genetics , Ubiquitin-Protein Ligases/immunologyABSTRACT
We present an elderly diabetic man with left hallux pain and drainage who was initially diagnosed with acute gouty arthritis using the diagnostic rule for acute gout and monosodium urate crystals presented on synovial fluid analysis. Further investigation with surgical debridement, plain X-ray, MRI and wound culture revealed concomitant Citrobacter koseri septic arthritis with osteomyelitis. C. koseri is considered an opportunistic infection that rarely causes musculoskeletal infections. Acute gouty arthritis and septic arthritis are rarely seen occurring concomitantly in the same joint and are often difficult to differentiate due to similar findings on exam and imaging. The present case illustrates that osteomyelitis with an opportunistic organism can present concomitantly with acute gouty arthritis, and the diagnosis of one should not exclude the other.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Arthritis, Gouty/microbiology , Citrobacter koseri/pathogenicity , Diabetic Foot/physiopathology , Enterobacteriaceae Infections/diagnosis , Ertapenem/therapeutic use , Osteomyelitis/diagnosis , Aged, 80 and over , Arthritis, Gouty/therapy , Debridement , Diabetic Foot/microbiology , Enterobacteriaceae Infections/physiopathology , Enterobacteriaceae Infections/therapy , Humans , Male , Osteomyelitis/physiopathology , Osteomyelitis/therapy , Piperacillin, Tazobactam Drug Combination/therapeutic use , Treatment Outcome , Vancomycin/therapeutic useABSTRACT
A late preterm male infant of 36 weeks gestation and a birth weight of 2100 g was admitted on day 35 of life with complaints of respiratory distress and lethargy. He was diagnosed as a case of sepsis screen positive culture negative sepsis and was managed with respiratory support and intravenous antibiotics for 10 days. The infant improved clinically and was on spoon feeds by day 14 of admission. On day 14 of admission, he developed new-onset respiratory distress and was diagnosed as a case of nosocomial pneumonia based on chest radiography findings. The blood culture grew a rare organism Cedecea lapagei and a diagnosis of sepsis was also made. The antibiotics were tailored as per the blood culture sensitivity pattern and the infant had clinical improvement in the next 72 hours.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Enterobacteriaceae Infections/diagnosis , Enterobacteriaceae/isolation & purification , Piperacillin, Tazobactam Drug Combination/therapeutic use , Respiration, Artificial , Respiratory Distress Syndrome, Newborn/microbiology , Sepsis/diagnosis , Enterobacteriaceae/classification , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/physiopathology , Humans , Infant , Lethargy , Male , Respiration, Artificial/adverse effects , Respiratory Distress Syndrome, Newborn/drug therapy , Respiratory Distress Syndrome, Newborn/physiopathology , Sepsis/drug therapy , Spinal Puncture , Treatment OutcomeABSTRACT
Although catfish are found worldwide and commonly consumed in the southern United States, fatal infections from catfish are rare. Edwardsiella tarda is a bacterium known to cause gastrointestinal distress most commonly, but extraintestinal infections are a rarely considered danger for those acquiring, preparing, and consuming aquatic animals. Susceptible to all gram-negative active antibiotics, it is easily treated except in immunocompromised hosts, such as those with malignancy, diabetes, and hepatic dysfunction.
Subject(s)
Bites and Stings/therapy , Catfishes/microbiology , Edwardsiella tarda/isolation & purification , Enterobacteriaceae Infections/diagnosis , Animals , Bites and Stings/microbiology , Enterobacteriaceae Infections/complications , Enterobacteriaceae Infections/pathology , Enterobacteriaceae Infections/physiopathology , Fatal Outcome , Humans , Male , Middle Aged , Shock, Septic/microbiologyABSTRACT
BACKGROUND: Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are disseminating worldwide leading to increased hospital length of stay and mortality in intensive care units (ICU). ESBL-E dissemination was first due to outbreaks in hospital settings which led to the implementation of systematic fecal carriage screening to improve hygiene procedures by contact precautions. ESBLs have since spread in the community, and the relevance of contact precautions is questioned. ESBL-E dissemination led to an overuse of carbapenems triggering the emergence of carbapenem-resistant Enterobacteriaceae. Empirical antimicrobial therapy based on ESBL-E fecal carriage has been proposed but is debated as it could increase the consumption of carbapenems among ESBL-E carriers without any clinical benefit. Finally, selective decontamination among ESBL-E fecal carriers is evoked to decrease the risk for subsequent ESBL-E infection, but its efficacy remains debated. We propose to systematically review the evidence to recommend or not such systematic ESBL-E fecal carriage screening in adult ICU. METHODS: Every article focusing on ESBL-E and ICU available on the MEDLINE database was assessed. Articles were included if focusing on cross-transmission, efficacy of hygiene procedures, link between ESBL-E colonization and infection or guidance of empirical therapy or selective decontamination efficacy. RESULTS: Among 330 articles referenced on PubMed, 39 abstracts were selected for full-text assessment and 25 studies were included. Systematic screening of ESBL-E fecal carriage to guide contact precautions do not seem to decrease the rate of ESBL-E cross-transmission. It has a very good negative predictive value for subsequent ESBL-E infections but a positive predictive value between 40 and 50% and so does not help to spare carbapenems. Cessation of ESBL-E carriage systematic screening could decrease the use of carbapenems in ICU without any clinical harm. Nevertheless, further studies are needed to validate these results from monocentric before-after study. Selective decontamination strategy applied to ESBL-E fecal carriers could be helpful, but available data are conflicting. CONCLUSION: Current knowledge lacks of high-quality evidence to strongly recommend in favor of or against a systematic ESBL-E fecal carriage screening policy for ICU patients in a non-outbreak situation. Further evaluation of selective decontamination or fecal microbiota transplantation among ESBL-E fecal carriers is needed.
Subject(s)
Carrier State/diagnosis , Feces/microbiology , Mass Screening/methods , beta-Lactamases/analysis , Adult , Carrier State/physiopathology , Cross Infection/prevention & control , Enterobacteriaceae/metabolism , Enterobacteriaceae/pathogenicity , Enterobacteriaceae Infections/diagnosis , Enterobacteriaceae Infections/physiopathology , Enterobacteriaceae Infections/prevention & control , Female , Humans , Intensive Care Units/organization & administration , Male , Mass Screening/trends , Microbial Sensitivity Tests/methods , beta-Lactamases/adverse effects , beta-Lactamases/metabolismABSTRACT
Patients with chemotherapy-induced febrile neutropenia (FN) are vulnerable to extended-spectrum b-lactamase-producing Enterobacteriaceae (ESBL-PE) infection. Early identification of patients suspected to have ESBL-PE infection for empirical carbapenem administration is crucial; nevertheless, risk factors for ESBL-PE causing septic shock remain unclear. We identify factors to predict ESBL-PE in septic shock patients with chemotherapy-induced FN. In this observational, prospectively collected registry-based study, consecutive adult chemotherapy-induced FN patients with septic shock who were admitted to the emergency department between June 2012 and June 2018 were enrolled. Clinical and laboratory data extracted from the septic shock registry were assessed to identify risk factors for ESBL-PE. Of 179 chemotherapy-induced FN septic shock patients, ESBL-PE is isolated in 23 (12.8%). ESBL-PE infection is frequently seen in patients with hepatobiliary cancer (17.4% vs. 4.5%, P = 0.037), leukemia (13.0% vs. 2.6%, P = 0.046), and those with profound neutropenia (defined as absolute neutrophil count < 100) (73.9% vs. 43.6%, P = 0.007) in contrast to those with lung cancer (0% vs. 14.7%, P = 0.048) and other solid cancer (0% vs. 19.2%, P = 0.016). Multivariate logistic regression reveals that profound neutropenia (adjusted OR 3.67; 95% CI 1.372-9.799; P = 0.010) is an independent risk factor for ESBL-PE infection after adjusting age, the presence of solid tumor, and the parameters of sepsis severity scores. ESBL-PE is rare (12.9%) in chemotherapy-induced FN patients with septic shock. Early empirical carbapenem therapy might be considered in chemotherapy-induced FN patients with profound neutropenia.
Subject(s)
Chemotherapy-Induced Febrile Neutropenia/etiology , Enterobacteriaceae Infections/complications , Shock, Septic/etiology , APACHE , Aged , Chi-Square Distribution , Drug Therapy/methods , Enterobacteriaceae/drug effects , Enterobacteriaceae/pathogenicity , Enterobacteriaceae Infections/physiopathology , Female , Humans , Male , Middle Aged , Neoplasms/complications , Neoplasms/drug therapy , Neoplasms/physiopathology , Organ Dysfunction Scores , Prevalence , Prospective Studies , Republic of Korea , Risk Factors , Shock, Septic/physiopathology , Statistics, NonparametricABSTRACT
BACKGROUND: Cedecea lapagei bacterium was discovered in 1977 but was not known to be pathogenic to humans until 2006. In the medical literature there are very few clinical case reports of Cedecea lapagei; none have reported a catastrophic death secondary to a soft tissue hemorrhagic bullae infection. As well as soft tissue infection, rare cases of pneumonia, urinary tract infections, peritonitis, osteomyelitis, bacteremia, and sepsis have been documented with the majority having good outcomes. Here, we present the first case of a fatal outcome in a Cedecea lapagei soft tissue infection with multiple hemorrhagic bullae. CASE PRESENTATION: A 52-year-old Mexican man with antecedents of liver cirrhosis and treated hypertension was brought to our institution with clinical signs of sepsis and 16 to 18 hours of history of pain and edema in his right lower limb. During the course of the first day hospitalized in our institution, he developed several large serohematogenous bullae with ascending progression on his entire right lower limb. He subsequently developed multiple organ failure and septic shock with rapid deterioration, dying on the second day. Bullae fluid samples taken the first day undoubtedly isolated Cedecea lapagei within the second day using MicroScan WalkAway® 96 plus System as well Gram-negative bacteria in MacConkey and blood agar. CONCLUSIONS: The isolation of Cedecea lapagei was an unexpected etiological finding that will enable physicians in the future to consider this bacterium as a probable cause of serohematogenous bullae infections. We do not exclude contamination although it has never been isolated in bullae fluid in the medical literature. Future encounters with this bacterium should not be taken lightly as it may have the potential to have fatal outcomes.
Subject(s)
Blister/microbiology , Enterobacteriaceae Infections/complications , Enterobacteriaceae Infections/physiopathology , Lower Extremity/microbiology , Lower Extremity/physiopathology , Shock, Septic/etiology , Shock, Septic/physiopathology , Enterobacteriaceae Infections/diagnosis , Fatal Outcome , Humans , Male , Mexico , Middle AgedABSTRACT
Plazomicin is an FDA-approved aminoglycoside for the treatment of complicated urinary tract infections. In this open-label study, 24 adults with normal renal function or mild, moderate, or severe renal impairment (n = 6 per group) received a single 7.5-mg/kg of body weight dose of plazomicin as a 30-min intravenous infusion. Total clearance declined with renal impairment, resulting in 1.98-fold and 4.42-fold higher plazomicin exposures, as measured by the area under the concentration-time curve from 0 h to infinity, in subjects with moderate and severe impairment, respectively, than in subjects with normal renal function. (This study has been registered at ClinicalTrials.gov under identifier NCT01462136.).
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Enterobacteriaceae Infections/drug therapy , Renal Insufficiency/drug therapy , Sisomicin/analogs & derivatives , Urinary Tract Infections/drug therapy , Aged , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacology , Area Under Curve , Drug Administration Schedule , Enterobacteriaceae/drug effects , Enterobacteriaceae/pathogenicity , Enterobacteriaceae/physiology , Enterobacteriaceae Infections/blood , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/physiopathology , Female , Humans , Infusions, Intravenous , Kidney/drug effects , Kidney/microbiology , Kidney/physiopathology , Kidney Function Tests , Male , Middle Aged , Renal Insufficiency/blood , Renal Insufficiency/microbiology , Renal Insufficiency/physiopathology , Severity of Illness Index , Sisomicin/blood , Sisomicin/pharmacokinetics , Sisomicin/pharmacology , Urinary Tract Infections/blood , Urinary Tract Infections/microbiology , Urinary Tract Infections/physiopathologyABSTRACT
BACKGROUND: Carbapenemases-producing Enterobacteriaceae (CPE) are a worldwide public health emergency. In Mexico, reports of CPE are limited, particularly in the pediatric population. Here, we describe the clinical, epidemiological, and molecular characteristics of seven consecutive cases in a third-level pediatric hospital in Mexico City over a four-month period during 2016. RESULTS: The Enterobacteriaceae identified were three Escherichia coli strains (producing OXA-232, NDM-1 and KPC-2), two Klebsiella pneumoniae strains (producing KPC-2 and NDM-1), one Klebsiella oxytoca strain producing OXA-48 and one Enterobacter cloacae strain producing NDM-1. The majority of patients had underlying disesases, three were immunocompromised, and three had infections involved the skin and soft tissues. Half patients died as a result of CPE infection. CONCLUSIONS: This study represents the first report of E. coli ST131-O25b clone producing NDM-1 in Latin America. In addition, this study is the first finding of K. oxytoca producing OXA-48 and E. coli producing OXA-232 in Mexican pediatric patients.
Subject(s)
Carbapenem-Resistant Enterobacteriaceae/enzymology , Carbapenem-Resistant Enterobacteriaceae/pathogenicity , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Adolescent , Carbapenem-Resistant Enterobacteriaceae/genetics , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Child , Child, Preschool , Enterobacter cloacae/enzymology , Enterobacter cloacae/genetics , Enterobacter cloacae/isolation & purification , Enterobacter cloacae/pathogenicity , Enterobacteriaceae Infections/mortality , Enterobacteriaceae Infections/physiopathology , Escherichia coli/enzymology , Escherichia coli/genetics , Escherichia coli/isolation & purification , Escherichia coli/pathogenicity , Female , Genotype , Hospitals, Pediatric , Humans , Infant , Klebsiella oxytoca/enzymology , Klebsiella oxytoca/genetics , Klebsiella oxytoca/isolation & purification , Klebsiella oxytoca/pathogenicity , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/isolation & purification , Klebsiella pneumoniae/pathogenicity , Latin America/epidemiology , Male , Mexico/epidemiology , Microbial Sensitivity Tests , Molecular Epidemiology , beta-Lactamases/metabolismABSTRACT
BACKGROUND: Close contact between pets and owners provides the opportunity for transmission of antimicrobial resistant organisms like extended-spectrum beta-lactamase (ESBL)/AmpC beta-lactamase (AmpC)-producing Enterobacteriaceae, posing a risk to public health. OBJECTIVES: To investigate whether raw feed is a risk factor for household cats to shed ESBL-producing Enterobacteriaceae, a cohort study was designed. Additionally, raw and non-raw commercial pet food products were screened for the presence of ESBL-producing Enterobacteriaceae. METHODS: Weekly fecal samples of 17 cats in the control group and 19 cats in the exposed group were collected for three weeks and analyzed for the presence of ESBL-producing Enterobacteriaceae. Questionnaires were obtained to determine additional risk factors. Fecal samples were cultured on MacConkey agar supplemented with 1 mg/L cefotaxime. PCR and sequence analysis was used for screening for ESBL genes in suspected isolates. Pet food samples were cultured in LB broth supplemented with 1 mg/L cefotaxime and processed as described above. RESULTS: In the cohort study, ESBL-producing bacteria were isolated from 3 of 51 (5.9%) samples in the control group compared to 37 of 57 (89.5%) samples in the exposed group. A significant association was found between ESBL shedding and feeding raw pet food products (OR = 31.5). No other risk factors were identified in this study. ESBL-producing Enterobacteriaceae were isolated from 14 of 18 (77.8%) raw pet food products and 0 of 35 non-raw pet food products. CONCLUSIONS: This study shows a strong association between shedding of ESBL-producing bacteria in household cats and feeding raw pet food. Raw pet food was often contaminated with ESBL-producing Enterobacteriaceae.
Subject(s)
Animal Feed , Enterobacteriaceae Infections/physiopathology , Pets , Animals , Cats , Risk FactorsABSTRACT
Carbapenemase-producing Enterobacteriaceae have been steadily spreading worldwide during the last decade. Nine patients were identified prospectively and were followed during their hospitalization course to identify the epidemiology, clinical profiles and outcomes. These patients had one or more cultures positive for a CRE isolate, contributing to a total of eleven positive cultures from various sites without including duplicates of isolates obtained from the same site. Isolates from these patients included five Klebseilla pneumoniae, three Escherichia coli, and one Enterobacter aerogenes. Five isolates were grown from blood cultures, three from wound cultures, one from urine cultures, one from respiratory cultures and one from an abscess collection. Five survived the hospital course. The other five patients died due to severe sepsis, septic shock or multi-organ failure. Of the nine isolates of CRE identified for which molecular analysis were available, four K. pneumonia were confirmed as blaNDM and one as OXA-48. For the purpose of controlling the spread of CRE in our institution, we recommend considering active surveillance cultures and screening patients transferred from other hospitals or coming from highly endemic settings at admission for these organisms.
Subject(s)
Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Communicable Diseases, Emerging/microbiology , Enterobacteriaceae Infections/microbiology , Hospitals, University , Adult , Aged , Carbapenems , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/physiopathology , Enterobacter aerogenes/drug effects , Enterobacter aerogenes/isolation & purification , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/physiopathology , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Female , Humans , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Male , Middle Aged , Prospective Studies , Saudi Arabia/epidemiologyABSTRACT
Brain abscesses due to Enterobacteriaceae in immune-competent children are rare, and those due to Enterobacter cloacae are even rarer. We report an interesting case of community-acquired E. cloacae neuroinfection resulting in multiple brain abscesses in a young child with no underlying risk-factors. A 10 year-old-boy presented with low-grade fever, headache, neck pain and progressive deterioration of sensorium. On examination, he was conscious but drowsy with photophobia, normal fundii, meningeal signs, mild hypertonia, brisk muscle stretch reflexes and extensor plantar responses. Magnetic resonance imaging of brain showed bilateral, multiple pyogenic abscesses. Culture of the abscess material aspirated at the time of surgical drainage showed growth of E. cloacae. He received intravenous imipenem for 18 weeks guided by clinical and radiological response. A pragmatic approach combining early surgical drainage, targeted antimicrobial therapy and patient-tailored duration based on the clinico-radiological response is needed in such difficult cases.
Subject(s)
Brain Abscess/microbiology , Enterobacter cloacae , Enterobacteriaceae Infections/microbiology , Brain/pathology , Brain Abscess/diagnostic imaging , Brain Abscess/immunology , Child , Community-Acquired Infections/diagnostic imaging , Community-Acquired Infections/microbiology , Enterobacteriaceae Infections/diagnostic imaging , Enterobacteriaceae Infections/immunology , Enterobacteriaceae Infections/physiopathology , Humans , Magnetic Resonance Imaging , MaleABSTRACT
Actin is one of the most abundant cellular proteins and an essential constituent of the actin cytoskeleton, which by its dynamic behavior participates in many cellular activities. The organization of the actin cytoskeleton is regulated by a large number of proteins and represents one of the major targets of bacterial toxins. A number of bacterial effector proteins directly modify actin: Clostridial bacteria produce toxins, which ADP-ribosylate actin at Arg177 leading to inhibition of actin polymerization. The bacterium Photorhabdus luminescens produces several types of protein toxins, including the high molecular weight Tc toxin complex, whose component TccC3 ADP-ribosylates actin at Thr148 promoting polymerization and aggregation of intracellular F-actin leading to inhibition of several cellular functions, such as phagocytosis. Here, we review recent findings about the functional consequences of these actin modifications and for the Thr148-ADP-ribosylated actin the subsequent alterations in the interaction with actin-binding proteins . In addition, we describe the effects of ADP-ribosylation of Rho GTPases by the TccC5 component.